Whether cobimetinib (cobimetinib) has been included in medical insurance and details of the 2025 reimbursement policy

Cobimetinib (Cobimetinib) is a new oral MEK inhibitor, mainly used to treat patients with advanced melanoma carrying BRAF V600 mutations. It is usually used in combination with BRAF inhibitors to enhance efficacy and delay the occurrence of drug resistance. However, in terms of domestic medical insurance and reimbursement policies, cobimetinib has not yet been included in China’s national medical insurance catalog, and patients still need to pay for its use in full. Due to its limited time in the domestic market, drug supply and hospital accessibility may not be perfect.

As for the reimbursement policy for 2025, cobimetinib is still not covered by medical insurance in China, so there are currently no official reimbursement regulations. If patients need to use this drug, they usually need to obtain it through formal overseas channels or hospital imported drug projects. Due to the lack of medical insurance support, the cost of use is high. Patients need to fully evaluate their financial affordability and treatment necessity before use, and formulate individualized medication plans under the guidance of professional doctors.

In overseas markets, the original drug cobimetinib has been launched in many countries. For example, in Japan, the specifications of the Japanese version of the original drug are 25mg/bottles*8bottles, and each box sells for about 2 RMB 25,000 (affected by exchange rate fluctuations). There are currently no publicly available generic drugs on the market, which means patients still have to rely on the supply of original drugs in overseas markets. The price of the drug is relatively high, but its clinical efficacy and safety have been strictly verified, and it has important therapeutic value for patients with advanced melanoma who meet the indications.

Generally speaking, cobimetinib has not yet been included in medical insurance in China, and patients need to purchase it at their own expense. The reimbursement policy is not feasible in the short term. Overseas original drugs are expensive. If domestic patients want to use them, they need to pay attention to the legality of import channels and drug quality assurance. With the advancement of the domestic marketing approval process and the gradual improvement of medical insurance policies, cobimetinib is expected to gain wider accessibility in the country in the future, providing an effective targeted treatment option for patients with BRAF V600 mutated advanced melanoma.

Reference materials:https://www.drugs.com/